Glenmark Pharma gets ANDA nod for Sevelamer Hydrochloride Tablets

According to IQVIA sales data for the 12-month period ending December 2018, the Renagel tablets, 400 mg and 800 mg market achieved annual sales of approximately $102.1mn.

Feb 11, 2019 09:02 IST India Infoline News Service

Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Sevelamer Hydrochloride Tablets, 400mg and 800mg, a generic version of Renagel tablets, 400mg and 800mg, of Genzyme Corporation.

According to IQVIA sales data for the 12-month period ending December 2018, the Renagel tablets, 400mg and 800mg market achieved annual sales of approximately $102.1mn.

Glenmark’s current portfolio consists of 149 products authorized for distribution in the US marketplace and 53 ANDAs pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Related Story